Website
News25/Ratings2
News · 26 weeks36-86%
2025-10-262026-04-19
Mix1590d
- Insider7(47%)
- SEC Filings4(27%)
- Earnings3(20%)
- Other1(7%)
Latest news
25 items- PRTELA Bio to Announce First Quarter 2026 Financial ResultsMALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2026 financial results on Tuesday, May 12, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the
- SECSEC Form S-8 filed by TELA Bio Inc.S-8 - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 10-K filed by TELA Bio Inc.10-K - TELA Bio, Inc. (0001561921) (Filer)
- SECTELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Reports Fourth Quarter and Full Year 2025 Financial ResultsMALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024;Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear;Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer
- SECTELA Bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - TELA Bio, Inc. (0001561921) (Filer)
- INSIDERNew insider Langstein Howard N. claimed ownership of 71,347 shares (SEC Form 3)3 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio to Announce Fourth Quarter and Full Year 2025 Financial ResultsMALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15
- INSIDERChief Executive Officer Koblish Antony was granted 176,000 shares and covered exercise/tax liability with 28,025 shares, decreasing direct ownership by 0.66% to 586,210 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Business Officer Firestone Gregory A. was granted 37,000 shares and covered exercise/tax liability with 5,541 shares, increasing direct ownership by 29% to 139,307 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Technology Officer Talmo Paul was granted 57,000 shares and covered exercise/tax liability with 7,446 shares, increasing direct ownership by 40% to 173,436 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERPresident Blizard Jeffrey was granted 86,000 shares, increasing direct ownership by 72% to 205,125 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERCOO and CFO Cuca Roberto was granted 57,000 shares and covered exercise/tax liability with 10,014 shares, increasing direct ownership by 22% to 257,377 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- INSIDERChief Accounting Officer Smeykal Megan was granted 32,850 shares and covered exercise/tax liability with 2,808 shares, increasing direct ownership by 82% to 66,873 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 8,550 shares of its common stock to three newly-hired employees, with a grant date of February 18, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h
- SECSEC Form 424B3 filed by TELA Bio Inc.424B3 - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form EFFECT filed by TELA Bio Inc.EFFECT - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h
- SECSEC Form S-3 filed by TELA Bio Inc.S-3 - TELA Bio, Inc. (0001561921) (Filer)
- PRTELA Bio to Participate in the Piper Sandler 37th Annual Healthcare ConferenceMALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference. TELA's management is scheduled to present at Piper Sandler's 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritiz
- INSIDERLarge owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)4 - TELA Bio, Inc. (0001561921) (Issuer)
- PRTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individua
- SECTELA Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - TELA Bio, Inc. (0001561921) (Filer)
- SECSEC Form 424B5 filed by TELA Bio Inc.424B5 - TELA Bio, Inc. (0001561921) (Filer)